{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:36:46Z","timestamp":1791567406893,"version":"4.3.4"},"reference-count":95,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Age-related Macular Degeneration (AMD) is a severe eye illness that is going to lead\nin the race for incurable blindness globally among the elderly population. AMD is the third\ncommon reason responsible for affecting the quality of life globally. The macula and the retinal\nlayers are adversely affected during AMD and are responsible for the loss of vision eventually.\nNumerous genetic variables, lipid metabolism, ageing and oxidative damage are the causative\nfactors in the genesis of AMD. Lack of antioxidants, smoking and excessive alcohol intake contribute\nto increasing the risk of AMD. Management of dry AMD involves the use of nutritional\nsupplements like zinc and antioxidants, along with conventional treatment, however, the use of\nnutritional supplements can only give minor benefits on the progression of dry AMD. Later\nstages of AMD need to be managed by cell-based interventions where the damaged or lost cells\nare replaced with fresh donor cells. A plethora of treatment methods are used in the management\nof AMD, such as nutrition, antibody-based treatments, stem cell management and nanotherapeutics.\nThe available expensive treatments come with a number of adverse effects and\nfuture developments require the involvement of risk factor modification approaches, personalized\ntherapy, targeting the disease specific pathways, exploring better anti-vascular endothelial\ngrowth factor (VEGF) inhibitors and many other regenerative approaches, that will broaden\ntechniques to diagnose, control and treat AMD. This review provides an overview of the progression\nof AMD and the causative factors, with considerable emphasises on the current and\npotential prospects.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0125899775250144230920053548","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T06:23:37Z","timestamp":1696227817000},"page":"59-75","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Management and New Upcoming Approaches for Age Related Macular Degeneration"],"prefix":"10.2174","volume":"17","author":[{"given":"Srishti","family":"Shetty","sequence":"first","affiliation":[{"name":"Shobhaben Pratapbhai Patel, School of Pharmacy &amp; Technology Management, SVKM\u2019s NMIMS, V.L. Mehta Road,\nVile Parle (W), MUMBAI, 400056, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Singh","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel, School of Pharmacy &amp; Technology Management, SVKM\u2019s NMIMS, V.L. Mehta Road,\nVile Parle (W), MUMBAI, 400056, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4166-3380","authenticated-orcid":true,"given":"Kalyani","family":"Barve","sequence":"additional","affiliation":[{"name":"Shobhaben Pratapbhai Patel, School of Pharmacy &amp; Technology Management, SVKM\u2019s NMIMS, V.L. Mehta Road,\nVile Parle (W), MUMBAI, 400056, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","volume":"105","author":"Thomas C.J.","year":"2021","unstructured":"Thomas C.J.; Mirza R.G.; Gill M.K.; Frcs C.; Age-Related Macular Degeneration. Med Clin North Am  2021,105(3),473-491","journal-title":"Med Clin North Am"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ophtha.2020.04.019","volume":"127","author":"Rim T.H.","year":"2020","unstructured":"Rim T.H.; Kawasaki R.; Tham Y.; Prevalence and Pattern of Geographic Atrophy in Asia: The Asian Eye Epidemiology Consortium. Ophthalmology  2020,127(10),1371-1381","journal-title":"Ophthalmology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.oret.2020.06.012","volume":"5","author":"Nittala M.G.","year":"2021","unstructured":"Nittala M.G.; Uji A.; Velaga S.B.; Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration. Ophthalmol Retina  2021,5(1),32-40","journal-title":"Ophthalmol Retina"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"120499","DOI":"10.1016\/j.ijpharm.2021.120499","volume":"600","author":"Kumar Dubey S.","year":"2021","unstructured":"Kumar Dubey S.; Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift. Int J Pharm  2021,600,120499","journal-title":"Int J Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"Colijn J.M.","year":"2017","unstructured":"Colijn J.M.; Buitendijk G.H.S.; Prokofyeva E.; Prevalence of Age-Related Macular Degeneration in Europe. Ophthalmology  2017,124(12),1753-1763","journal-title":"Ophthalmology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"103523","DOI":"10.1016\/j.mcn.2020.103523","volume":"107","author":"Morizur L.","year":"2020","unstructured":"Morizur L.; Herardot E.; Monville C.; Ben M\u2019Barek K.; Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration. Mol Cell Neurosci  2020,107(January),103523","journal-title":"Mol Cell Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/1874364101913010090","volume":"13","author":"Salimiaghdam N.","year":"2019","unstructured":"Salimiaghdam N.; Riazi-Esfahani M.; Fukuhara P.S.; Schneider K.; Kenney M.C.; Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors. Open Ophthalmol J  2019,13(1),90-99","journal-title":"Open Ophthalmol J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jjns.12257","volume":"17","author":"Kim C.G.","year":"2020","unstructured":"Kim C.G.; Park S.; Kim Y.; Age\u2010related macular degeneration among the elderly: The 5th National Health and Nutrition Examination Survey, 2010 through 2012. Jpn J Nurs Sci  2020,17(1),1-11","journal-title":"Jpn J Nurs Sci"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.3390\/nu11092123","volume":"11","author":"Health E.","year":"2019","unstructured":"Health E.; Nutrition and Eye Health. Nutrients  2019,11(9),2123-14","journal-title":"Nutrients"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"100858","DOI":"10.1016\/j.preteyeres.2020.100858","volume":"79","author":"Kaarniranta K.","year":"2020","unstructured":"Kaarniranta K.; Progress in Retinal and Eye Research Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. Prog Retin Eye Res  2020,79,100858","journal-title":"Prog Retin Eye Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.optom.2013.07.002","volume":"6","author":"Mousavi M.","year":"2013","unstructured":"Mousavi M.; Armstrong R.A.; Genetic risk factors and age-related macular degeneration (AMD). J Optom  2013,6(4),176-184","journal-title":"J Optom"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms21218242","volume":"21","author":"Ricci F.","year":"2020","unstructured":"Ricci F.; Bandello F.; Navarra P.; Staurenghi G.; Stumpp M.; Zarbin M.; Neovascular age-related macular degeneration: Therapeutic management and new-upcoming approaches. Int J Mol Sci  2020,21(21),8242","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.004","volume":"48","author":"Nazari H.","year":"2015","unstructured":"Nazari H.; Zhang L.; Zhu D.; Stem cell based therapies for age-related macular degeneration: The promises and the challenges. Prog Retin Eye Res  2015,48(June),1-39","journal-title":"Prog Retin Eye Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.4114","volume":"36","author":"da Cruz L.","year":"2018","unstructured":"da Cruz L.; Fynes K.; Georgiadis O.; Phase 1 clinical study of an embryonic stem cell\u2013derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol  2018,36(4),328-337","journal-title":"Nat Biotechnol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/17425247.2021.1888925","volume":"18","author":"Sharma P.","year":"2021","unstructured":"Sharma P.; Mittal S.; Expert Opinion on Drug Delivery Nanotechnology\u202f: Revolutionizing the delivery of drugs to treat age-related macular degeneration. Expert Opin Drug Deliv  2021,18(8),1131-1149","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/14712598.2021.1915278","volume":"21","author":"Ferro Desideri L.","year":"2021","unstructured":"Ferro Desideri L.; Traverso C.E.; Nicol\u00f2 M.; Ferro L.; Traverso C.E.; Nicol\u00f2 M.; Brolucizumab: A novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD. Expert Opin Biol Ther  2021,21(5),553-561","journal-title":"Expert Opin Biol Ther"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2021.02.009","author":"Deng Y.","year":"2021","unstructured":"Deng Y.; Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis   (Feb):2021","journal-title":"Genes Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.oret.2019.04.021","volume":"3","author":"Takagi S.","year":"2019","unstructured":"Takagi S.; Mandai M.; Gocho K.; Evaluation of Transplanted Autologous Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in Exudative Age-Related Macular Degeneration. Ophthalmol Retina  2019,3(10),850-859","journal-title":"Ophthalmol Retina"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/02713683.2019.1691237","volume":"45","author":"Vitillo L.","year":"2020","unstructured":"Vitillo L.; Tovell V.E.; Coffey P.; Treatment of Age-Related Macular Degeneration with Pluripotent Stem Cell-Derived Retinal Pigment Epithelium. Curr Eye Res  2020,45(3),361-371","journal-title":"Curr Eye Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"101787","DOI":"10.1016\/j.scr.2020.101787","volume":"45","author":"Kamata K.","year":"2020","unstructured":"Kamata K.; Otsuka Y.; Imamura K.; Generation of a human induced pluripotent stem cell line, BRCi004-A, derived from a patient with age-related macular degeneration. Stem Cell Res (Amst)  2020,45(February),101787","journal-title":"Stem Cell Res (Amst)"},{"key":"ref=21","author":"Degeneration A.M.","year":"2020","unstructured":"Degeneration A.M.;  Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease  Available From:  https:\/\/ichgcp.net\/clinical-trials-registry\/publications\/91290-stem-cell-ophthalmology-treatment-study-scots-bone-marrowderived-stem-cells-in-the-treatment-of-42020","journal-title":"Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.mam.2012.04.005","volume":"33","author":"Bhutto I.","year":"2012","unstructured":"Bhutto I.; Lutty G.; Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor\/retinal pigment epithelium\/Bruch\u2019s membrane\/choriocapillaris complex. Mol Aspects Med  2012,33(4),295-317","journal-title":"Mol Aspects Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.clinthera.2021.08.011","volume":"43","author":"Schultz N.M.","year":"2021","unstructured":"Schultz N.M.; Bhardwaj S.; Barclay C.; Gaspar L.; Schwartz J.; Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther  2021,43(10),1792-1818","journal-title":"Clin Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1038\/s41598-020-67292-z","volume":"10","author":"Armento A.","year":"2020","unstructured":"Armento A.; Honisch S.; Panagiotakopoulou V.; Loss of Complement Factor H impairs antioxidant capacity and energy metabolism of human RPE cells. Sci Rep  2020,10(1),10320","journal-title":"Sci Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","volume":"3","author":"Pennington K.L.","year":"2016","unstructured":"Pennington K.L.; DeAngelis M.M.; Epidemiology of age-related macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond)  2016,3(1),34","journal-title":"Eye Vis (Lond)"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"Mettu P.S.","year":"2021","unstructured":"Mettu P.S.; Allingham M.J.; Cousins S.W.; Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res  2021,82,100906","journal-title":"Prog Retin Eye Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"118767","DOI":"10.1016\/j.ijpharm.2019.118767","volume":"573","author":"Luaces-rodr\u00edguez A.","year":"2020","unstructured":"Luaces-rodr\u00edguez A.; Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration. Int J Pharm  2020,573,118767","journal-title":"Int J Pharm"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/08820538.2011.577131","volume":"26","author":"Olson J.H.","year":"2011","unstructured":"Olson J.H.; Erie J.C.; Bakri S.J.; Nutritional supplementation and age-related macular degeneration. Semin Ophthalmol  2011,26(3),131-136","journal-title":"Semin Ophthalmol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaophthalmol.2022.1640","volume":"140","author":"Chew E.Y.","year":"2022","unstructured":"Chew E.Y.; Clemons T.E.; Agr\u00f3n E.; Long-term Outcomes of Adding Lutein\/Zeaxanthin and \u03c9-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression. JAMA Ophthalmol  2022,140(7),692","journal-title":"JAMA Ophthalmol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1755-3768.2011.02357.x","volume":"91","author":"Sin H.Y.P.","year":"2013","unstructured":"Sin H.Y.P.; Liu D.T.L.; Lam D.S.C.; Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. Acta Ophthalmol  2013,91(1),6-11","journal-title":"Acta Ophthalmol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.nutres.2013.10.011","volume":"34","author":"Zampatti S.","year":"2014","unstructured":"Zampatti S.; Ricci F.; Cusumano A.; Marsella L.T.; Novelli G.; Giardina E.; Review of nutrient actions on age-related macular degeneration. Nutr Res  2014,34(2),95-105","journal-title":"Nutr Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.1038\/srep20723","volume":"6","author":"Aoki A.","year":"2016","unstructured":"Aoki A.; Inoue M.; Nguyen E.; Dietary n-3 Fatty Acid, \u03b1-Tocopherol, Zinc, vitamin D, vitamin C and \u03b2-carotene are Associated with Age-Related Macular Degeneration in Japan. Sci Rep  2016,6(1),20723","journal-title":"Sci Rep"},{"key":"ref=33","first-page":"30","volume":"18","author":"Lister T.","year":"2019","unstructured":"Lister T.; Nutritional, Alternative, and Complementary Therapies for Age-related Macular Degeneration. Integr Med (Encinitas)  2019,18(6),30-36","journal-title":"Integr Med (Encinitas)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antiox8040085","volume":"8","author":"Khoo H.E.","year":"2019","unstructured":"Khoo H.E.; Ng H.S.; Yap W.; Ji H.; Goh H.; Yim H.S.; Nutrients for Prevention of Macular Degeneration and Eye-Related Diseases. Antioxidants (Basel)  2019,8(4),4-85","journal-title":"Antioxidants (Basel)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/nu10080959","volume":"10","author":"Olmedilla-Alonso B.","year":"2018","unstructured":"Olmedilla-Alonso B.; Effect of long-term xanthophyll and anthocyanin supplementation on Lutein and Zeaxanthin Serum Concentrations and macular pigment optical density in postmenopausal women. Nutrients  2018,10(8),4-959","journal-title":"Nutrients"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"8583","DOI":"10.1167\/iovs.14-15573","volume":"55","author":"Hammond B.R.","year":"2014","unstructured":"Hammond B.R.; Fletcher L.M.; Roos F.; Wittwer J.; Schalch W.; A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast. Invest Ophthalmol Vis Sci  2014,55(12),8583-8589","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.mam.2012.03.005","volume":"33","author":"Weikel K.A.","year":"2012","unstructured":"Weikel K.A.; Chiu C.J.; Taylor A.; Nutritional modulation of age-related macular degeneration. Mol Aspects Med  2012,33(4),318-375","journal-title":"Mol Aspects Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ophtha.2009.10.043","volume":"117","author":"Christen W.G.","year":"2010","unstructured":"Christen W.G.; Glynn R.J.; Chew E.Y.; Buring J.E.; Vitamin E and Age-Related Macular Degeneration in a Randomized Trial of Women. Ophthalmology  2010,117(6),1163-1168","journal-title":"Ophthalmology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.3390\/ijms21144994","volume":"21","author":"Blasiak J.","year":"2020","unstructured":"Blasiak J.; Pawlowska E.; Chojnacki J.; Szczepanska J.; Chojnacki C.; Kaarniranta K.; Zinc and Autophagy in age-related macular degeneration. Int J Mol Sci  2020,21(14),4994","journal-title":"Int J Mol Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/07315724.2018.1538830","volume":"38","author":"Arslan S.","year":"2019","unstructured":"Arslan S.; Kadayif\u00e7ilar S.; Samur G.; The Potential Role of Dietary Antioxidant Capacity in Preventing Age-Related Macular Degeneration. J Am Coll Nutr  2019,38(5),424-432","journal-title":"J Am Coll Nutr"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41598-019-38934-8","volume":"9","author":"Wecker T.","year":"2019","unstructured":"Wecker T.; Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Sci Rep  2019,9(1),3301","journal-title":"Sci Rep"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5114\/ceji.2016.63132","volume":"3","author":"Po\u017carowska D.","year":"2016","unstructured":"Po\u017carowska D.; Po\u017carowski P.; The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol  2016,3(3),311-316","journal-title":"Cent Eur J Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.22608\/APO.2017260","volume":"6","author":"Cheung G.C.M.","year":"2017","unstructured":"Cheung G.C.M.; Lai T.Y.Y.; Gomi F.; Ruamviboonsuk P.; Koh A.; Lee W.K.; Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy. Asia Pac J Ophthalmol (Phila)  2017,6(6),527-534","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e000257","DOI":"10.1136\/bmjophth-2018-000257","volume":"4","author":"Clearkin L.","year":"2019","unstructured":"Clearkin L.; Ramasamy B.; Wason J.; Tiew S.; Anti-VEGF intervention in neovascular AMD: Benefits and risks restated as natural frequencies. BMJ Open Ophthalmol  2019,4(1),e000257","journal-title":"BMJ Open Ophthalmol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2016.03.002","volume":"787","author":"Eandi C.M.","year":"2016","unstructured":"Eandi C.M.; Alovisi C.; De Sanctis U.; Grignolo F.M.; Treatment for neovascular age related macular degeneration: The state of the art. Eur J Pharmacol  2016,787,78-83","journal-title":"Eur J Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"Schmidt-Erfurth U.","year":"2014","unstructured":"Schmidt-Erfurth U.; Chong V.; Loewenstein A.; Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol  2014,98(9),1144-1167","journal-title":"Br J Ophthalmol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ajo.2014.05.014","volume":"158","author":"Lad E.M.","year":"2014","unstructured":"Lad E.M.; Hammill B.G.; Qualls L.G.; Wang F.; Cousins S.W.; Curtis L.H.; Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. Am J Ophthalmol  2014,158(3),537-543.e2","journal-title":"Am J Ophthalmol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","volume":"123","author":"Jaffe G.J.","year":"2016","unstructured":"Jaffe G.J.; Kaiser P.K.; Thompson D.; Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Ophthalmology  2016,123(9),1856-1864","journal-title":"Ophthalmology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","volume":"127","author":"Sadda S.R.","year":"2020","unstructured":"Sadda S.R.; Guymer R.; Mon\u00e9s J.M.; Tufail A.; Jaffe G.J.; Anti\u2013Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration. Ophthalmology  2020,127(5),648-659","journal-title":"Ophthalmology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12325-016-0461-z","volume":"34","author":"Andr\u00e9s-Guerrero V.","year":"2017","unstructured":"Andr\u00e9s-Guerrero V.; Perucho-Gonz\u00e1lez L.; Garc\u00eda-Feijoo J.; Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. Adv Ther  2017,34(2),378-395","journal-title":"Adv Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"Manzano R.P.A.","year":"2006","unstructured":"Manzano R.P.A.; Peyman G.A.; Khan P.; Kivilcim M.; Testing intravitreal toxicity of Bevacizumab (Avastin). Retina  2006,26(3),257-261","journal-title":"Retina"},{"key":"ref=52","year":"2004","unstructured":"Center for Drug evaluation and research, Review and Evaluation of Toxicology Data of Bevacizumab. Avastin  Available From:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/STN-125085_Avastin_Toxr.pdf2004","journal-title":"Avastin"},{"key":"ref=53","year":"2018","unstructured":"Centers for Disease Control and Prevention NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings: Proposed Additions to the NIOSH Hazardous Drug List 2018 Peer Review Comments The NIOSH  Available From:  https:\/\/www.federalregister.gov\/documents\/2018\/02\/14\/2018-02957\/niosh-list-of-antineoplastic-and-other-hazardous-drugs-in-healthcare-settings-proposed-additions-to2018","journal-title":"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings: Proposed Additions to the NIOSH Hazardous Drug List 2018 Peer Review Comments The NIOSH"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3129\/i10-024","volume":"45","author":"Xu W.","year":"2010","unstructured":"Xu W.; Wang H.; Wang F.; Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. Can J Ophthalmol  2010,45(4),386-392","journal-title":"Can J Ophthalmol"},{"key":"ref=55","year":"2005","unstructured":"Center for Drug evaluation and research Pharmacology\/Toxicology Review and Evaluation on Lucentis, ranibizumab - BLA application number 125156  Available From:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125156Orig1s106.pdf2005","journal-title":"Pharmacology\/Toxicology Review and Evaluation on Lucentis, ranibizumab - BLA application number 125156"},{"key":"ref=56","year":"2007","unstructured":"EMEA Scientific discussion of lucentis  2007","journal-title":"Scientific discussion of lucentis"},{"key":"ref=57","year":"2012","unstructured":"Center for drug evaluation and research, Center for Drug Evaluation\tand Pharmacology Review: Zaltrap.  Available From:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125418Orig1s000PharmR.pdf2012"},{"key":"ref=58","year":"2020","unstructured":"Bayer Inc Product Monograph Eylea  2020","journal-title":"Product Monograph Eylea"},{"key":"ref=59","year":"2012","unstructured":"Committee for Medicinal Products for Human Use (EMA) Eylea (Aflibercept) EPAR Assessment Report  2012"},{"key":"ref=60","year":"2013","unstructured":"Committee for Medicinal Products for Human Use (EMA) Assessment report: Eylea  Available From:   https:\/\/www.ema.europa.eu\/en\/documents\/assessmentreport\/eylea-epar-public-assessment-report_en.pdf2013","journal-title":"Assessment report: Eylea"},{"key":"ref=61","year":"2006","unstructured":"EMEA Pegaptanib  Available From:  https:\/\/en.wikipedia.org\/wiki\/Pegaptanib2006","journal-title":"Pegaptanib"},{"key":"ref=62","unstructured":"CDER, \u201cPharmacology Reviews 2004"},{"key":"ref=63","year":"2013","unstructured":"Pfizer, Product monograph: Macugen.  Available From:\n https:\/\/pdf.hres.ca\/dpd_pm\/00022292.PDF2013"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/DDDT.S67536","volume":"9","author":"Sun X.","year":"2015","unstructured":"Sun X.; Lu X.; Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther  2015,9,2311-2320","journal-title":"Drug Des Devel Ther"},{"key":"ref=65","year":"2019","unstructured":"CDER Summary Review of Brolicizumab  Available From:  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125Orig1s000SumR.pdf2019","journal-title":"CDER Summary Review of Brolicizumab"},{"key":"ref=66","unstructured":"CDER, Non-Clinical Review(s) of Brolicizumab. 2019."},{"key":"ref=67","year":"2019","unstructured":"Committee for Medicinal Products for Human Use (EMA), Assessment Report Beovu - Brolucizumab.  2019"},{"key":"ref=68","year":"2020","unstructured":"Novartis Pharmaceuticals Canada Inc, Product Monograph Including Patient Medication Information BEOVU Available From  2020","journal-title":"Available From"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2147\/DDDT.S295223","volume":"15","author":"Hussain R.M.","year":"2021","unstructured":"Hussain R.M.; Shaukat B.A.; Ciulla L.M.; Berrocal A.M.; Sridhar J.; Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. Drug Des Devel Ther  2021,15,2653-2665","journal-title":"Drug Des Devel Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.oret.2019.10.008","volume":"4","author":"Dugel P.U.","year":"2020","unstructured":"Dugel P.U.; Boyer D.S.; Antoszyk A.N.; Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. Ophthalmol Retina  2020,4(3),250-263","journal-title":"Ophthalmol Retina"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/S1525-0016(16)33058-1","volume":"24","author":"Scaria A.","year":"2016","unstructured":"Scaria A.; LeHalpere A.; Purvis A.; 249. Preliminary Results of a Phase 1, Open-Label, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients with Neovascular Age-Related Macular Degeneration. Mol Ther  2016,24,S98","journal-title":"Mol Ther"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"Mitchell P.","year":"2018","unstructured":"Mitchell P.; Liew G.; Gopinath B.; Wong T.Y.; Age-related macular degeneration. Lancet  2018,392(10153),1147-1159","journal-title":"Lancet"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/bjophthalmol-2018-313462","volume":"103","author":"Wong C.W.","year":"2019","unstructured":"Wong C.W.; Wong T.T.; Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. Br J Ophthalmol  2019,103(10),1356-1360","journal-title":"Br J Ophthalmol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"Khanna S.","year":"2019","unstructured":"Khanna S.; Komati R.; Eichenbaum D.A.; Hariprasad I.; Ciulla T.A.; Hariprasad S.M.; Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: A comparative review. BMJ Open Ophthalmol  2019,4(1),e000398","journal-title":"BMJ Open Ophthalmol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"Ohji M.","year":"2020","unstructured":"Ohji M.; Takahashi K.; Okada A.A.; Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR. Adv Ther  2020,37(3),1173-1187","journal-title":"Adv Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.molimm.2019.11.007","volume":"118","author":"Simmons K.T.","year":"2020","unstructured":"Simmons K.T.; Complement Receptor 1 (CR1\/CD35)-expressing retinal pigment epithelial cells as a potential therapy for age-related macular degeneration. Mol Immunol  2020,118,91-98","journal-title":"Mol Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.tins.2013.03.006","volume":"36","author":"Carr A.J.F.","year":"2013","unstructured":"Carr A.J.F.; Smart M.J.K.; Ramsden C.M.; Powner M.B.; da Cruz L.; Coffey P.J.; Development of human embryonic stem cell therapies for age-related macular degeneration. Trends Neurosci  2013,36(7),385-395","journal-title":"Trends Neurosci"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.10.054","author":"Sarkar A.","year":"2020","unstructured":"Sarkar A.; Dyawanapelly S.; Nanodiagnostics and Nanotherapeutics for age-related macular degeneration Nanodiagnostics and Nanotherapeutics for age-related macular degeneration. J Control Release  (October):2020","journal-title":"J Control Release"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","volume":"193","author":"Kaur I.P.","year":"2014","unstructured":"Kaur I.P.; Kakkar S.; Nanotherapy for posterior eye diseases. J Control Release  2014,193,100-112","journal-title":"J Control Release"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","volume":"6","author":"Li F.","year":"2012","unstructured":"Li F.; Hurley B.; Liu Y.; Leonard B.; Griffith M.; Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration. Open Ophthalmol J  2012,6,54-58","journal-title":"Open Ophthalmol J"},{"key":"ref=81","author":"Strong H.A.","year":"1999","unstructured":"Strong H.A.; Levy J.; Huber G.; Fsadni M.;  Vision through photodynamic\ttherapy of the eye  1999","journal-title":"Vision through photodynamic\ttherapy of the eye"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/smll.201303433","volume":"10","author":"Davis B.M.","year":"2014","unstructured":"Davis B.M.; Normando E.M.; Guo L.; Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small  2014,10(8),1575-1584","journal-title":"Small"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/jphp.12587","volume":"68","year":"2016","unstructured":"Dexamethasone - PAMAM dendrimer conjugates for retinal\tdelivery: Preparation, characterization and in vivo evaluation. J\tPharm Pharmacol 2016 Aug;68(8):1010-20  2016,68(8),1010-1020","journal-title":"J\tPharm Pharmacol 2016 Aug;68(8):1010-20"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","volume":"248","author":"Mandal A.","year":"2017","unstructured":"Mandal A.; Bisht R.; Rupenthal I.D.; Mitra A.K.; Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release  2017,248,96-116","journal-title":"J Control Release"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/scipharm88030030","volume":"88","author":"Streets J.","year":"2020","unstructured":"Streets J.; Bhatt P.; Bhatia D.; 2020; Sunitinib-Loaded MPEG-PCL micelles for the treatment of age-related macular degeneration. Scientia Pharmaceutica  2020,88(3),30","journal-title":"Scientia Pharmaceutica"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1208\/s12249-019-1404-1","volume":"20","author":"Alshamrani M.","year":"2019","unstructured":"Alshamrani M.; Sikder S.; Coulibaly F.; Mandal A.; Pal D.; Mitra A.K.; Self-Assembling Topical Nanomicellar Formulation to Improve Curcumin Absorption Across Ocular Tissues. AAPS PharmSciTech  2019,20(7),254","journal-title":"AAPS PharmSciTech"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jddst.2016.10.009","volume":"36","author":"Lim C.","year":"2016","unstructured":"Lim C.; Kim D.; Sim T.; Preparation and characterization of a lutein loading nanoemulsion system for ophthalmic eye drops. J Drug Deliv Sci Technol  2016,36,168-174","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"112212","DOI":"10.1016\/j.msec.2021.112212","volume":"127","author":"Fang G.","year":"2021","unstructured":"Fang G.; Yang X.; Wang Q.; Zhang A.; Tang B.; Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases. Mater Sci Eng C  2021,127(May),112212","journal-title":"Mater Sci Eng C"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1038\/s41598-017-03959-4","volume":"7","author":"Sousa F.","year":"2017","unstructured":"Sousa F.; Cruz A.; Fonte P.; Pinto I.M.; Neves-Petersen M.T.; Sarmento B.; A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci Rep  2017,7(1),3736","journal-title":"Sci Rep"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1080\/10717544.2018.1474967","volume":"25","author":"Mu H.","year":"2018","unstructured":"Mu H.; Wang Y.; Chu Y.; Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Deliv  2018,25(1),1372-1383","journal-title":"Drug Deliv"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.02.003","volume":"541","author":"Luis de Red\u00edn I.","year":"2018","unstructured":"Luis de Red\u00edn I.; Boiero C.; Mart\u00ednez-Oh\u00e1rriz M.C.; Human serum albumin nanoparticles for ocular delivery of bevacizumab. Int J Pharm  2018,541(1-2),214-223","journal-title":"Int J Pharm"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jphotobiol.2018.04.033","volume":"183","author":"Yan J.","year":"2018","unstructured":"Yan J.; Peng X.; Cai Y.; Cong W.; Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy. J Photochem Photobiol B  2018,183,133-136","journal-title":"J Photochem Photobiol B"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/adt.2019.920","volume":"17","author":"Narvekar P.","year":"2019","unstructured":"Narvekar P.; Bhatt P.; Fnu G.; Sutariya V.; Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and In Vitro Characterization. Assay Drug Dev Technol  2019,17(4),167-177","journal-title":"Assay Drug Dev Technol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"8819","DOI":"10.2147\/IJN.S217038","volume":"14","author":"Liu J.","year":"2019","unstructured":"Liu J.; Zhang X.; Li G.; Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications. Int J Nanomedicine  2019,14,8819-8834","journal-title":"Int J Nanomedicine"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jddst.2017.01.004","volume":"38","author":"Hoshikawa A.","year":"2017","unstructured":"Hoshikawa A.; Tagami T.; Morimura C.; Fukushige K.; Ozeki T.; Ranibizumab biosimilar\/polyethyleneglycol-conjugated gold nanoparticles as a novel drug delivery platform for age-related macular degeneration. J Drug Deliv Sci Technol  2017,38,45-50","journal-title":"J Drug Deliv Sci Technol"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775250144230920053548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221538\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0125899775250144230920053548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:06:11Z","timestamp":1741241171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221538\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0125899775250144230920053548","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}